Board approves Sub-division of Equity Shares
Natco Pharma Ltd has informed BSE that the Board of Directors of the Company at its meeting held on August 12, 2015, inter alia, has approved the following items and recommended to the members for their approval in the ensuing Annual General Meeting:1. Sub-division of face value of equity shares of the Company from Rs. 10/- (rupees ten only) each to that of Rs. 2/- (rupees two only) each.... Announces Q1 results, Limited Review Report & Results Press Release for the Quarter ended June 30, 2015
Natco Pharma Ltd has announced the following results for the quarter ended June 30, 2015 :The Un-Audited Standalone results for the Quarter ended June 30, 2015: The Company has posted a net profit of Rs. 340.70 million for the quarter ended June 30, 2015 as compared to Rs. 364.10 million for the quarter ended June 30, 2014. Total Income has increased from Rs. 1823.60 million for the quarter ended June 30, 2014 to Rs. 1968.80 million for the quarter ended June 30, 2015.... Q1 results on August 12, 2015
Natco Pharma Ltd has informed BSE that a meeting of the Board of Directors of the Company will be held on August 12, 2015, inter alia, to consider the following items of businesses and related matters:1. Various options of raising of funds for one of the subsidiaries Timecap Overseas Ltd., Mauritius to be used for investment in Natcofarma Do Brasil Ltda, Brasil.... Shareholding Pattern For June 30, 2015
Natco Pharma Ltd has informed BSE about the Shareholding Pattern as on June 30, 2015. Updates on Outcome of EGM
Natco Pharma Ltd has submitted to BSE a copy of the proceedings of the Extraordinary General Meeting of the Members of the Company held on June 27, 2015. Details of the voting results at the EGM (Clause 35A & 35B)
Natco Pharma Ltd has informed BSE about Details of the voting results at the Extra Ordinary General Meeting of the Company held on June 27, 2015, as per Clause 35A & 35B of Listing Agreement. The Company has also submitted to BSE a copy of Scrutinizer Report in this regard. Outcome of EGM
Natco Pharma Ltd has informed BSE that the Extra Ordinary General Meeting (EGM) of the Company was held on June 27, 2015. EGM on June 27, 2015
Natco Pharma Ltd has informed BSE that the Extra Ordinary General Meeting (EGM) of the Company will be held on June 27, 2015. U.S. Court of Appeals for the Federal Circuit Finds Teva'S 808 COPAXONE Patent Invalid
Natco Pharma Ltd has informed BSE regarding a Press Release dated June 19, 2015 titled "U.S. Court of Appeals for the Federal Circuit Finds Teva'S 808 COPAXONE Patent Invalid" Results Press Release
Natco Pharma Ltd has submitted to BSE a copy of Results Press Release for the period ended March 31, 2015.